Can-Fite BioPharma (CANF) Announces Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million

Can-Fite: Summary of Existing Out-licensing Deals with Potential Milestone Payments of up to approximately $130 million

In addition, to date ~$20 million in non-dilutive upfront payment received

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the six existing... More